CLINICAL TRIALS PROFILE FOR BESIFLOXACIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for besifloxacin hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00347932 ↗ | A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. | Completed | Bausch & Lomb Incorporated | Phase 3 | 2006-06-01 | Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis. |
| NCT00348348 ↗ | A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 3 | 2006-06-01 | This is a study to investigate a novel drug candidate for the treatment of bacterial conjunctivitis. |
| NCT00407589 ↗ | Systemic Pharmacokinetics of BOL-303224-A | Completed | Bausch & Lomb Incorporated | Phase 1 | 2006-10-01 | This is a multi-center, open-label, single dose/multiple dose, pharmacokinetic study in participants with bacterial conjunctivitis. The purpose of this study is to determine the extent of systemic exposure to BOL-303224-A following single and multiple topical administration of BOL-303224-A in participants with suspected bacterial conjunctivitis. |
| NCT00622908 ↗ | Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis | Completed | Bausch & Lomb Incorporated | Phase 2 | 2004-12-01 | To evaluate the clinical and microbial efficacy of ISV-403 administered three times a day (TID) for 5 days compared to vehicle three times a day for 5 days in the treatment of bacterial conjunctivitis |
| NCT00824070 ↗ | Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects | Completed | Bausch & Lomb Incorporated | Phase 1 | 2009-02-01 | This study is being conducted to assess the concentration of besifloxacin, moxifloxacin, or gatifloxacin in aqueous humor samples collected following topical instillation of the associated formulation in subjects undergoing cataract surgery. |
| NCT00905762 ↗ | Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation | Completed | Bausch & Lomb Incorporated | Phase 1 | 2009-03-01 | The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days. |
| NCT00924729 ↗ | Study of Ocular Penetration of Topically Administered Fluoroquinolones | Completed | Johns Hopkins University | Phase 4 | 2009-09-01 | This study is being conducted to evaluate the intraocular penetration of Moxifloxacin 0.5% ophthalmic solution (Vigamox) and Besifloxacin 0.6% ophthalmic suspension (Besivance) after pre-operative topical administration in subjects undergoing cataract surgery. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for besifloxacin hydrochloride
Condition Name
Clinical Trial Locations for besifloxacin hydrochloride
Trials by Country
Clinical Trial Progress for besifloxacin hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for besifloxacin hydrochloride
Sponsor Name
